Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT ID: NCT00193518
Last Updated: 2011-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
41 participants
INTERVENTIONAL
2004-04-30
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
NCT00005618
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT00081133
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
NCT01522469
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
NCT01925131
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
NCT00985530
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Arsenic Trioxide
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arsenic Trioxide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically proven B-cell CLL/SLL.
* Must have had a minimum of 1 and a maximum of 3 previous systemic regimens
* Must have progressive CLL/SLL
* Measurable or evaluable disease
* ECOG performance status 0, 1, or 2
* Age \> 18 years.
* Patients with cytopenias caused by bone marrow involvement are eligible
* All patients must give written informed consent prior to entering this study.
Exclusion Criteria
* Unstable active infection on the basis of neutropenia
* Previous severe opportunistic infections
* Severe immune mediated anemia or thrombocytopenia
* Serious underlying medical conditions
* Brain metastases or meningeal involvement
* History of other neoplasms
* Significant underlying heart dysfunction
* Women who are pregnant or
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CTI BioPharma
INDUSTRY
SCRI Development Innovations, LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SCRI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John D. Hainsworth, MD
Role: PRINCIPAL_INVESTIGATOR
SCRI Development Innovations, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCRI LYM 33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.